INmune Bio prices $4.5 million offering, confirms Feb 2027 UK filing for RDEB therapy

INmune Bio Inc. announced the pricing of a $4.5 million offering on October 28, 2026, a day after entering into the underlying securities purchase agreement on October 27, 2026. The company agreed to issue and sell 3,000,000 shares of common stock in a registered direct offering at $1.50 per share.¹ INmune Bio expects aggregate gross proceeds of $4.5 million from the offering, before deducting placement agent fees and offering expenses.¹ The offering is expected to close on October 29, 2026, subject to customary closing conditions.¹ A.G.P./Alliance Global Partners is acting as sole placement agent.¹

In a concurrent private placement, the company also agreed to issue unregistered warrants to purchase up to 3,000,000 shares of common stock.¹ The warrants carry an exercise price of $1.65 per share, become exercisable on April 27, 2027, and expire on April 27, 2032.¹ Net proceeds are intended to support the development of CORDStrom and for working capital and general corporate purposes.²

On the regulatory front, the prospectus supplement dated October 27, 2026 gives updated specifics on the UK filing timeline for the company's lead RDEB program. On October 21, 2026, the company announced it had submitted its final pre-Marketing Authorisation Application package to the UK MHRA for Ebstrocel (CORDStrom), and revised prior guidance to indicate that faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review.² This replaces the sequential rolling submission previously planned to begin in late 2026, and the company believes the new approach could accelerate potential UK approval by approximately six weeks from prior guidance.² The company anticipates an MHRA response within three to six months after submission, subject to application validation, agency review and any requests for additional information.²